{"id":"W4367302706","doi":"10.1212/wnl.0000000000202314","title":"Phase 1/2 Clinical Study of VRDN-001, A Full Antagonist Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients with Thyroid Eye Disease (TED) (P3-9.001)","year":2023,"lang":"en","type":"article","venue":"Neurology","topic":"Ophthalmology and Eye Disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Lakeridge Health","funders":"","keywords":"Medicine; Placebo; Tolerability; Diplopia; Internal medicine; Antagonist; Clinical endpoint; Gastroenterology; Randomized controlled trial; Surgery; Adverse effect; Receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001686727,0.001679635,0.00162051,0.0003399197,0.0003496521,0.0007459248,0.000880365,0.001280371,0.004980705],"category_scores_gemma":[0.001061782,0.0006782874,0.0009709982,0.0002851404,0.0008368424,0.0008419352,0.0002838463,0.002574235,0.000919135],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007342212,"about_ca_system_score_gemma":0.001311158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007820957,"about_ca_topic_score_gemma":0.002179733,"domain_scores_codex":[0.999585,0.0002047513,0.00001737886,0.00007171799,0.00003809477,0.00008303921],"domain_scores_gemma":[0.9994251,0.0001148555,0.000142026,0.00004447123,0.00004136084,0.0002322935],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.830712,0.06099648,0.003230612,0.0007120881,0.0008448649,0.0001819114,0.0002187983,0.001367483,0.04691437,0.0002007504,0.003728505,0.0508921],"study_design_scores_gemma":[0.7934625,0.1981658,0.004257918,0.00001652411,0.0002003486,0.0001251474,0.00002260158,0.0005078147,0.001908943,0.00009268981,0.001221508,0.00001815712],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889277,0.001768623,0.001052859,0.0004718328,0.0001526424,0.00415425,0.001666573,0.0001588488,0.001646597],"genre_scores_gemma":[0.979968,0.001646114,0.003794028,0.001335691,0.0002976637,0.006459731,0.002572065,0.00006866299,0.003858184],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004980705,"threshold_uncertainty_score":0.01666212,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02348927210802151,"score_gpt":0.35168030947685,"score_spread":0.3281910373688285,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}